Actinium Pharmaceuticals Inc (ATNM)
AMEXHealth CareBiotechnologySnapshot 2026-09-09
$1.230.00%
Close 2026-09-09 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Maintain stockholders' equity above $4 million to meet NYSE standards: metric not reported.
Actinium aims to meet NYSE listing rules by improving stockholders' equity above $4 million. Operating losses have improved from -$16.6M to -$5.9M in one year. Cash flow from operations also improved from -$7.6M to -$5.9M. These steps show progress toward financial stability despite current losses.
The company is still losing money and faces delisting risk due to low equity. Recent CFO resignation adds uncertainty. Operating losses and negative cash flow persist, showing limited progress. The stock has fallen over 30% from its high, reflecting these risks.
The stock price is about 28% below our valuation level, reflecting the market's concerns about financial health and ongoing losses. Our view differs by focusing on the potential for stabilization if management meets key financial targets.
Breaks if: cash flow from operations worsens beyond -$5.9 million
Continue efforts to control operating losses and reduce negative cash flow from operations to improve financial sustainability.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on advancing clinical programs and improving financial performance. The current thesis state suggests cautious optimism as the company has shown signs of recovery, but challenges remain.
The market appears to price ATNM as relatively cheap compared to its peers, reflecting a gap in expectations. There is a low level of fragility in the current valuation, indicating that the market does not expect significant disruptions.
Management has made progress in improving financial performance, moving from losses to net income recently. However, the trajectory remains mixed as the company continues to work on advancing its clinical pipeline and regaining compliance with listing standards.
The future performance of ATNM hinges on the success of its clinical programs and the ability to regain compliance with NYSE standards. Additionally, the overall health of the healthcare sector and performance of key sector bellwethers will play a crucial role in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Valuation fell by 21.7 points (from 62.1 to 40.4).
No, our read on the company is unchanged. The recent financial performance remains strong. The sector backdrop is supportive, helping the company. There are no new threats or supports impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: stockholders' equity falls below $4 million
Address the NYSE American continued listing standards by improving stockholders' equity and financial health to avoid delisting.
Breaks if: additional key executive departures occur
Breaks if: operating loss worsens beyond -$5.9 million
Continue efforts to control operating losses and reduce negative cash flow from operations to improve financial sustainability.
In the next 1 to 3 years, ATNM's outlook will depend on its execution of strategic priorities and external market conditions. Not investment advice.